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ABSTRACT
Antiphospholipid syndrome (APS) is a disease characterized by 
recurrent arterial and venous thromboses. Rapidly progressive 
multiple thromboses leading to multiorgan failure occur in less 
than 1% of patients and named as catastrophic antiphospholipid 
syndrome (CAPS). We, hereby, describe an 8 year-old-girl with 
erythematous skin lesions progressing into purpura fulminans. The 
patient developed CAPS with the findings including proteinuria, 
microangiopathic hemolytic anemia, thrombocytopenia, arterial 
and venous thromboses demonstrated on skin biopsies. She was 
admitted to intensive care unit and received empirical antibiotics, 
anticoagulants, antiaggregants, steroids and intravenous 
immunoglobulins. The diagnosis of APS was confirmed by 
positive lupus anticoagulants, elevated anti beta-2 glycoprotein IgG 
and antiphospholipid IgG titers. Moreover, other than MTHFR-
A1298C, MTHFR-C677T, factor V H1299R, beta fibrinogen-455 
G>A heterozygosity indicating low risk for thrombophilia, no 
infectious, rheumatological or malignant etiologies were identified. 
Family history revealed Raynaud’s phenomenon in a sister, 
interstitial lung disease, proteinuria and hematuria in paternal 
grandmother in addition to lupus anticoagulant positivity in father 
and 2 elder sisters. Her treatment included debridement of necrotic 
skin tissue, grefting and local mesenchymal stem cell application 
to upper thigh and lower leg region following oral azathioprine 
administration. 
Keywords: Catastrofic antiphospholipid syndrome, Child, Purpura 
fulminans
ÖZ
Antifosfolipid antikor sendromu (AFAS) tekrarlayan venöz ve 
arteriyel trombozlarla seyreden bir hastalıktır. Hastaların %1’inden 
azında görülen hızlı seyirli, çoklu trombozlara bağlı multiorgan 
yetmezlik tablosu katastrofik antifosfolipid antikor sendromu 
(KAFAS) olarak adlandırılmaktadır. Burada eritematöz cilt 
lezyonlarıyla başvuran, takibinde alt ekstremitelerde yaygın purpura 
fulminans gelişen 8 yaşında kız çocuk sunulmaktadır. Hastada 
cilt tutulumuna ek olarak izlemde proteinüri, mikroanjiyopatik 
hemolitik anemiye eşlik eden trombositopeni gelişmesi ve cilt 
biyopsilerinde arteryel ve venöz trombozlar gösterilmesi nedeniyle 
KAFAS geliştiği düşünüldü. Hastaya yoğun bakım desteği ve 
geniş spektrumlu antimikrobiyal tedavilerin yanısıra antikoagulan, 
antiagregan, steroid, intravenöz immünoglobulin tedavileri 
uygulandı. Bu aşamada hastada lupus antikoagulan, anti beta-2 
glikoprotein ve antifosfolipid IgG pozitifliği saptanması üzerine 
AFAS tanısı doğrulandı. Ancak etiyolojiye yönelik araştırmalarda 
trombotik riski düşük MTHFR-A1298C, MTHFR-C677T, faktör 
V H1299R, beta fibrinojen-455 G>A mutasyonlarının heterozigot 
pozitifliği dışında romatolojik, enfeksiyöz ve malign nedenler 
saptanmadı. Aile öyküsünde; ablada Raynaud fenomeni, halada 
benzer cilt lezyonları, babaannede intersitisyel akciğer hastalığı ve 
proteinüri olmasının yanında baba ve iki ablada lupus antikoagulan 
pozitifliği saptandı. Yaygın cilt nekrozuna yönelik debridman, 
greftleme ve lokal mezankimal kök hücre tedavisinin yanısıra 
azatioprin tedavileri de uygulanan hastada cilt bulgularında 
belirgin düzelme gözlendi. 
Anahtar kelimeler: Katastrofik antifosfolipid antikor sendromu, 
Çocuk, Purpura fulminans
Introduction
Purpura fulminans (PF) is a rapidly progressive thrombotic 
disorder with hemorrhagic infarcts of skin and disseminated 
intravascular coagulation (DIC). In the etiology of childhood 
PF, infections, sepsis, autoimmune disease, protein C 
and S deficiency and antiphospholipid syndrome (APS) 
can be listed [1]. Among those, APS is characterized by 
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recurrent venous or arterial thrombosis and the presence 
of antiphospholipid antibodies including anticardiolipin, 
lupus anticoagulant, antibeta-2 glycoprotein [2]. Although 
concomitant autoimmune diseases may predispose to APS, 
it may also present without any underlying condition called 
primary APS [2]. Regardless of the etiology, less than 1% of 
patients with APS develop devastating form of the disease, 
called catastrophic APS (CAPS).  This accelerated form 
of APS, with multiple thromboses leads to multiple organ 
failure and even death [3-5].
We, hereby, report a pediatric case of CAPS due to 
primary APS with mildly affected family members.
Case Report
An eight-year-old otherwise healthy girl presented 
with painful necrotic and bullous lesions on the lower 
extremities. Reddish-purple lesions on the medial side of 
both calves gradually extended to purpura fulminans within 
one week (Figure 1). Physical examination was noted for 
large necrotic ulcer on the left leg and thigh, ecchymosed-
indurated lesions and a large bulla on her right leg (Figure 
1). Laboratory findings revealed; WBC:6.3x103/uL, 
absolute neutrophil count:3,500/uL, absolute lymphocyte 
count:2,100/uL, ESR:8 mm/hour, CRP:3.1mg/lt (0-8mg/
lt), PT:17s (11-13), APTT:33.4s (28-36), INR:1,39, 
fibrinogen: 129 mg/dl (200-400) and D-dimer: 0.31ug/
ml (0-0.5). Blood smear was not compatible with blastic 
transformation. Blood and urine biochemistries were in 
normal range for the age. Following the initial work-up of 
thrombophilia, hereditary thrombophilic and rheumatologic 
diseases were not detected. Protein C, S and antithrombin III 
levels were all within the normal ranges (Protein C: 145% 
(70-130), Protein S: 73% (70-113), AT3: 102% (80-120); 
respectively).  Autoimmune markers including ANA, anti-
ds DNA, c-ANCA, p-ANCA, anti-histon, anti SS-A and 
SS-B antibodies were all negative. Complement screen for 
C3 and C4 levels were normal. Screening for thrombophilia 
revealed heterozygosity of MTHFR-A1298C, MTHFR-
C677T, factor V H1299R, beta fibrinogen-455 G>A. Lower 
extremity Doppler ultrasonography revealed no arterial 
or venous thrombi in large vessels, whereas skin biopsies 
demonstrated plugging of numerous small vessels in the 
dermis and subcutaneous fatty tissue with thrombi.
In the follow-up, she developed hematuria and 
proteinuria (730mg/day). Skin lesions deteriorated and 
new lesions developed (Figure 1) despite the treatment 
with low molecular weight heparin (1 mg/kg/dose Q12hr) 
and empirical wide spectrum antimicrobials. On the 10th 
day of admission, she developed profound anemia (Hb: 
5.5g/dL (12.0-17.0)). Laboratory investigations were 
compatible with disseminated intravascular coagulation 
(DIC): thrombocytopenia (platelets: 31x 103/ uL (150-440x 
103/ uL)), prolonged prothrombin time of 17.8s (11-13s), 
activated partial thromboplastin time of 140s (28-36s) and 
decreased fibrinogen levels of 107.00 mg/dL (200-400 
mg/dL).  In the pediatric intensive care unit, she received 
heparin infusion (75U/kg loading dose followed by 20U/
kg/hr infusion), corticosteroid therapy (2mg/kg/day) and 
fresh frozen plasma. Further studies showed the positivity of 
lupus anticoagulants, elevated anti-b
2 
glycoprotein IgG and 
antiphospholipid IgG titers (Table I). Diagnosis of CAPS 
was settled by the positive sera, rapid clinical deterioration, 
characteristic skin lesions and thrombi at skin biopsy. 
Figure 1: Clinical follow-up of purpura fulminans. A: Large 
necrotic ulcers and ecchymosed-indurated lesions at presentation. 
B: Necrotic tissue is debrided before skin grafting C: Healed lesions 
after skin grafting and local mesenchymal stem cell application by 
plastic surgery
Family history was remarkable for a sister describing 
Reynaud’s phenomenon, parental aunt with similar skin 
lesions and grandmother with interstitial lung disease, 
hematuria and proteinuria. The family members were all 
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screened twice for antiphospholipid antibodies. Results of 
the lupus anticoagulant tests were positive for two sisters 
and the father (Table I). Maintenance therapy included a 
combination of corticosteroids (2mg/kg/day), intravenous 
immunoglobulins (1gr/kg/day for 3 days), azathioprine 
(1mg/kg/day), low molecular weight heparin (1 mg/kg/
dose Q12hr) and asetylsalicylic acid (80mg/day), nifedipine 
(0.5mg/kg/day), pentoxifylline 400 mg/dose (Q12hr). In 3 
months’ time, her necrotizing skin lesions healed following 
debridement, skin grafting and local mesenchymal stem cell 
application by plastic surgery (Figure 1). During  one-year 
follow-up, no new lesions or thrombotic event developed, 
antiphospholipid antibodies remained negative.  She is 
currently on warfarin (0.1mg/kg/day maintenance dose) 
and tapering regimen for azathioprine without a clinical and 
laboratory deterioration. 
Table I: Antiphospholipid antibodies and clinical findings of family members
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Lupus anticoagulant
(31.4- 43.4 s)
48,4/100.1/
48.9/30.9
45.7/39.4 44.5/39.1 56.3/39.3 39.7/41.7 NA
Anti-b
2 
glycoprotein IgG
(0-8 s)
17.7/2.6 3.1/ 2.4/ 6.2 3.1 NA
Anti-b
2 
glycoprotein IgA
(0-8 s)
1.5/1.2 1.4 0.6 6.1 10.7/1.6 NA
Anti-b
2 
glycoprotein IgM
(0-8 s)
1.6/1.7 1.5 1.7 3.3 1.9 NA
Anti- phospholipid IgG
(0-9 s)
10.4/2.5 8.2 4.7 6.9 7.7 NA
Anti- phospholipid IgM
(0-9 s)
1.5/2.5 1.6 1.4 3.5 4.7 NA
Anti- cardiolipin IgG
(0-10 s)
5.1/3.7 2.6 2.8 2.7 1,8 NA
Anti- cardiolipin IgM
(0-10 s)
1.3/3.1 1.0 0.7 2.0 0,9 NA
VDRL negative negative negative negative negative NA
Clinical features CAPS
PF
Raynaud’s
phenomenon
Interstitial lung 
disease, hematuria, 
proteinuria
PF
Abbreviations: CAPS: Catastrophic Antiphospholipid Syndrome PF: Purpura Fulminans NA: Not applicable VDRL: Venereal Disease Research Laboratory Test
Discussion
We hereby present a pediatric case of primary APS with 
purpura fulminans that rapidly progressed into CAPS. APS 
in pediatric population is a very rare entity and characterized 
by arterial and/or venous thrombosis and persistent presence 
of antiphospholipid antibodies [6].  Other characteristics 
of the disease are: clinical conditions such as livedo 
reticularis, chorea, thrombocytopenia, fetal loss and cardiac 
valve lesions with accompanying serological evidence of 
antiphospholipid antibodies that can cause thrombotic events 
of APS,  especially in adults [7]. Newly suggested subset 
of APS is defined as microangiopathic antiphospholipid 
syndrome (MAPS) including thrombotic microangiopathic 
conditions such as hemolytic uremic syndrome  (HUS), 
thrombotic thrombocytopenic purpura (TTP),  hemolysis, 
elevated liver enzymes, low platelets (HELLP) syndrome 
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and CAPS without large vessel occlusion [7]. Clinical 
heterogeneity at presentation and vast number of diseases in 
the etiology of APS keep the high index of suspicion as the 
best diagnostic tool.
Patients with CAPS may present with a wide range 
of symptoms depending on the involved system with 
multiple organ system involvement over a short period of 
time. Histopathological evidence of multiple small vessel 
thrombosis and presence of antiphospholipid antibodies 
confirms the diagnosis [4]. CAPS patients are classified 
either as definitive CAPS or according to the classifications 
proposed by Asherson et al. [8]. Our patient fulfills the 
criteria of definitive CAPS with skin, renal and hematological 
involvement along with antibody positivity [9]. 
Widespread cutaneous necrosis as an initial symptom 
is a rare presentation in childhood period [10]. Severe 
cutaneous necrosis was the first manifestation in our patient. 
In 2/3 of patients with primary CAPS there is a precipitating 
event, most frequently an infection [11]. In our case,  the 
upper respiratory tract infection may be speculated as the 
precipitating factor by history. Besides, it may be assumed 
that the presence of heterozygosity of low thrombophilic 
genes may have contributed to the rapid clinical deterioration 
in our patient, whereas there is inconsistent data about 
the association of these mutations with clinical symptoms 
in antiphospholipid antibodies positive patients [12,13]. 
Pediatric APS registry also investigated single nucleotide 
polymorphisms of inflammatory mediators for the role 
of development of APS in pediatric patients which ended 
without any firm conclusion [14]. Different options of 
treatment including steroids, anticoagulation, antiaggregants, 
plasma exchange, intravenous immunoglobulins, 
cyclophosphamide, rituximab, prostacyclin, ancrod and 
defibrotide [11,15,16] reflect the vast variety of etiology and 
organ involvement.  Our patient who had received most of 
these agents completed 1 year follow-up period without any 
new thrombotic event.
In conclusion, clinical heterogeneity and  etiology of 
APS and CAPS make the high index of suspicion the best 
diagnostic tool. Keeping the mortality in mind, prompt 
treatment is essential to provide a better clinical outcome.
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